Effect of dose fractionation of Testosterone on red blood cells in Transgender Me

Phase 3

Recruiting

• Conditions: Transsexualism; F64.0

• Registration Number: RBR-479v8tv
• Lead Sponsor: Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-10-27
• Last Update Posted: 29 May 2023
• Study Completion: 2026-01-01

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

Transgender men with and with a diagnosis of testosterone-induced erythrocytosis will be included.

Exclusion Criteria

Male transgender (MT) with polycythemia vera or secondary to other pathologies (chronic kidney disease, severe lung disease, chronic myeloid leukemia, lymphoma, liver diseases and Cushing's syndrome); MT using hormonal contraceptives or copper IUDs; MT with psychiatric conditions such as severe psychotic disorders, severe personality disorders.

Study & Design

• Study Type: Intervention
• Study Design: Not specified